Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Boston Scientific halts sales of angiographic catheters amid 2 serious injuries

2 September 2026 · By · Wire by Fusion42

Published

2 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 2 September 2026 · Fusion42 review

Boston Scientific has halted sales of its Imager II angiographic catheters following reports of tip degradation causing two serious injuries. The FDA issued an early alert warning of a life-threatening risk of embolism from device fragments obstructing blood flow.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

Regulators have raised the barrier for device makers with safety lapses linked to serious injury. You must reassess your product risk controls immediately to avoid market disruption or recalls.

◆ Coverage

1 source · 2 Sep 2026

◆ Related on Wire

◆ Topics

Medtechboston-scientificcathetersfda-alertmedical-safetyproduct-recall